BioNTech (Mfg Services) vs ReciBioPharm: CDMO Comparison
Side-by-side comparison of BioNTech (Mfg Services) and ReciBioPharm on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- BioNTech (Mfg Services) holds 8 active EMA GMP certificates; ReciBioPharm does not appear in EudraGMDP.
- ReciBioPharm maintains 3 MHRA / UK GMP certificates; BioNTech (Mfg Services) does not.
- BioNTech (Mfg Services) appears as a manufacturing partner on more matched clinical programs (24 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both BioNTech (Mfg Services) and ReciBioPharm qualify as mRNA/LNP manufacturers; ReciBioPharm carries the higher composite Signal Score for mRNA/LNP programs in this comparison.
What to evaluate for mRNA/LNP programs
Both BioNTech (Mfg Services) and ReciBioPharm qualify as mRNA/LNP CDMOs. When choosing between them for mRNA/LNP programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
IVT mRNA synthesis
Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.
LNP formulation
LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.
Plasmid / starting material
mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.
Cold chain & stability
mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.
Frequently asked: BioNTech (Mfg Services) vs ReciBioPharm
How do BioNTech (Mfg Services) and ReciBioPharm compare on European GMP coverage?
BioNTech (Mfg Services) holds 8 active EMA GMP certificates and 0 MHRA / UK certificates. ReciBioPharm holds 0 active EMA GMP certificates and 3 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — BioNTech (Mfg Services) or ReciBioPharm?
BioNTech (Mfg Services) is matched to 24 ClinicalTrials.gov records as a manufacturing partner; ReciBioPharm is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for mRNA/LNP manufacturing — BioNTech (Mfg Services) or ReciBioPharm?
Both BioNTech (Mfg Services) and ReciBioPharm are tagged as mRNA/LNP CDMOs in our directory, so both are credible options for mRNA/LNP programs. The most important differentiator for mRNA/LNP selection is typically ivt mrna synthesis: Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
BioNTech (Mfg Services) carries a Signal Score of 85/100 and ReciBioPharm carries 88/100 — essentially tied for ReciBioPharm. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →